Q-omics provides the consensus-scored ARPIN-AP3S2 profile across patient tissues and cancer cell-line models. ARPIN-AP3S2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ARPIN-AP3S2 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, ARPIN-AP3S2 RNA expression shows 18,976 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, COAD, and THYM as cancer lineages where ARPIN-AP3S2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARPIN-AP3S2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARPIN-AP3S2 survival associations across molecular data types. ARPIN-AP3S2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARPIN-AP3S2 RNA expression–survival associations across cancer types. High ARPIN-AP3S2 expression shows unfavorable associations in ACC and UVM, but favorable associations in KIRC, SCLC, UCS and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ARPIN-AP3S2 RNA expression.
This table summarizes ARPIN-AP3S2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ARPIN-AP3S2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARPIN-AP3S2 shows lower tumor expression in COAD, KICH, READ and LUSC and higher tumor expression in LIHC and BRCA. The COAD box plot shows higher ARPIN-AP3S2 RNA expression in normal versus tumor tissue (log2 FC = −0.533, t-test p < 0.001).
This table shows molecular features associated with ARPIN-AP3S2 in patient tissues and cancer cell lines. In patient samples, ARPIN-AP3S2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARPIN-AP3S2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OVARY.
